-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 26, Northeast Pharmaceutical issued an announcement stating that the company had recently inquired and learned on the platform of the “Registration Information Disclosure of APIs, Pharmaceutical Excipients and Packaging Materials” of the State Food and Drug Administration, and learned that the “Dapoxetine Hydrochloride” API registration application was passed Approved by CDE
Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRIs) drug, mainly suitable for the treatment of premature ejaculation (PE) patients aged 18 to 64 years old